Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)

被引:159
作者
Henwood, CJ
Gatward, T
Warner, M
James, D
Stockdale, MW
Spence, RP
Towner, KJ
Livermore, DM
Woodford, N
机构
[1] Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England
[2] Univ Hosp, Publ Hlth Lab, Nottingham NG7 2UH, England
关键词
D O I
10.1093/jac/49.3.479
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A survey was conducted of the antimicrobial susceptibilities of 595 Acinetobacter spp. isolated from routine clinical specimens in 54 sentinel laboratories throughout the UK during 2000. Isolates of the Acinetobacter baumannii complex (genomic groups 2, 3 and 13TU; n=443) were distinguished from other genomic groups (n=152) by PCR fingerprinting of tDNA spacer regions. MICs of amikacin, cefotaxime, ceftazidime, ciprofloxacin, colistin, gentamicin, imipenem, meropenem, minocycline, piperacillin, piperacillin/tazobactam, rifampicin, sulbactam and tetracycline were determined on IsoSensitest agar and interpreted, wherever possible, using BSAC breakpoints. Tigecycline (GAR-936), a new glycylcycline, was also tested. Resistance to cephalosporins, aminoglycosides and ciprofloxacin was widespread, but carbapenems, colistin, sulbactam, minocycline and tigecycline were each active against >80% of the isolates. Isolates of A. baumannii were more often resistant to cefotaxime, ceftazidime, piperacillin, piperacillin/tazobactam, ciprofloxacin, gentamicin and tetracyclines than those belonging to other genomic groups, but were less often resistant to colistin; no significant differences between genomic groups were noted in the susceptibilities to amikacin, carbapenems, rifampicin or sulbactam. The relative activities of the tetracyclines were minocycline > tigecycline > tetracycline. Thirteen carbapenem-resistant isolates (MICs greater than or equal to 8 mg/L; 2.2%) were received from six centres; four centres sent single isolates; one sent three and one sent six. An allele of bla(IMP) was detected in one of these isolates, but the other 12 isolates either had carbapenemase-independent resistance, or undetectable carbapenemase activity combined with other resistance mechanisms. In conclusion, carbapenems, colistin and minocycline retained greatest activity against the Acinetobacter isolates collected. Tigecycline was less active than minocycline, but both agents overcame most tetracycline resistance.
引用
收藏
页码:479 / 487
页数:9
相关论文
共 24 条
[1]   Characterization of OXA-25, OXA-26, and OXA-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii [J].
Afzal-Shah, M ;
Woodford, N ;
Livermore, DM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :583-588
[2]   BSAC standardized disc susceptibility testing method [J].
Andrews, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 :43-57
[3]   In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak [J].
Appleman, MD ;
Belzberg, H ;
Citron, DM ;
Heseltine, PNR ;
Yellin, AE ;
Murray, J ;
Berne, TV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :1035-1040
[4]   In vitro activities of ampicillin, sulbactam and a combination of ampicillin and sulbactam against isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolated in Chile between 1990 and 1998 [J].
Bello, H ;
Domínguez, M ;
González, G ;
Zemelman, R ;
Mella, S ;
Young, HK ;
Amyes, SGB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (05) :712-713
[5]   Acinetobacter spp, as nosocomial pathogens: Microbiological, clinical, and epidemiological features [J].
BergogneBerezin, E ;
Towner, KJ .
CLINICAL MICROBIOLOGY REVIEWS, 1996, 9 (02) :148-+
[6]   Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme:: High-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases [J].
Bou, G ;
Cerveró, G ;
Domínguez, MA ;
Quereda, C ;
Martínez-Beltrán, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (09) :3299-3305
[7]   Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance [J].
Chopra, I ;
Roberts, M .
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2001, 65 (02) :232-+
[8]   IMP-4, a novel metallo-β-lactamase from nosocomial Acinetobacter spp. collected in Hong Kong between 1994 and 1998 [J].
Chu, YW ;
Afzal-Shah, M ;
Houang, ETS ;
Palepou, MFI ;
Lyon, DJ ;
Woodford, N ;
Livermore, DM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :710-714
[9]   Acinetobacter species identification by using tRNA spacer fingerprinting [J].
Ehrenstein, B ;
Bernards, AT ;
Dijkshoorn, L ;
GernerSmidt, P ;
Towner, KJ ;
Bouvet, PJM ;
Daschner, FD ;
Grundmann, H .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (10) :2414-2420
[10]   Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates [J].
Gales, AC ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (01) :19-36